

Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases

MASARU KATO, TATSUYA ATSUMI, TAKASHI KURITA, TOSHIO ODANI, YUICHIRO FUJIEDA, KOTARO OTOMO, TETSUYA HORITA, SHINSUKE YASUDA, and TAKAO KOIKE

ABSTRACT. Objective. To evaluate the risk of reactivation of resolved hepatitis B virus (HBV) by immunosuppressive therapy in patients with autoimmune diseases.

Methods. Thirty-five patients with autoimmune diseases were included in our study; all were hepatitis B surface antigen (HBsAg)-negative and antibody against hepatitis B core antigen-positive. They were followed for 8–124 weeks and clinical outcomes were analyzed, including serum levels of HBV-DNA and aminotransferase every 4 weeks during their immunosuppressive therapy for underlying autoimmune diseases. If HBV-DNA was detected during the immunosuppressive therapy, HBsAg, antibody against HBsAg (anti-HBs), hepatitis B e antigen (HBeAg), and antibody against HBeAg were also monitored every 4 weeks.

Results. HBV-DNA was detected in 6 out of 35 patients. Anti-HBs titer was significantly lower in the patients in whom HBV-DNA was detected compared with the others at baseline: 2.83 (range 0.24–168.50) mIU/ml vs 99.94 (range 0.00–5342.98) mIU/ml, respectively ($p = 0.036$). Outcomes of the 6 patients with HBV reactivation were as follows: HBV-DNA turned negative in 2 patients without nucleic acid analog (NAA) and 1 with NAA; 2 died due to bacterial sepsis; and 1 died due to autoimmune hemolytic anemia. Significant elevation of aminotransferase was found in only 1 patient, but HBsAg converted to positive in 2 patients and HBeAg converted to positive in 1 patient.

Conclusion. Reactivation of resolved HBV can occur during standard immunosuppressive therapy for autoimmune diseases. The low titer of baseline anti-HBs at may carry its risk. (J Rheumatol First Release Aug 15 2011; doi:10.3899/jrheum.110289)

Key Indexing Terms:

HEPATITIS B VIRUS

IMMUNOSUPPRESSION

AUTOIMMUNE DISEASES

Reactivation of hepatitis B virus (HBV) in patients undergoing cytotoxic chemotherapy or immunosuppressive therapy is considered one of the most important complications of such treatments affecting prognosis^{1,2,3,4,5}. Prophylactic administration of nucleic acid analog (NAA) is recommended for HBV carriers during moderate or high intensity immunosuppressive therapies^{6,7,8}.

Clearance of hepatitis B surface antigen (HBsAg) with the appearance of antibody against HBsAg (anti-HBs) had been generally accepted as evidence of clinical cure of acute hepatitis B. However, in 2001 Dervite, *et al* first reported a possible relationship between HBV reactivation and use of rituximab in a patient with anti-HBs⁹. In 2006, a prospective study from Hong Kong revealed that 3.3% of patients who

were HBsAg-negative developed HBV reactivation after chemotherapy¹⁰. HBV replication persists at low levels in the liver for decades after acute hepatitis B^{11,12,13,14,15}. Hepatitis with reactivation of resolved HBV has frequently been reported^{16,17,18,19,20,21,22}. From these data, negative HBsAg with positive antibody against hepatitis B core antigen (anti-HBc) has been recently accepted as occult HBV infection. High mortality is of great clinical significance in reactivation of resolved HBV. An epidemiological study revealed that reactivation of resolved HBV was found in 23 (4%) of 552 patients who were newly HBsAg-positive; fulminant hepatic failure developed in 5 (22%) of these 23 cases with 100% mortality, and all 5 patients had received a treatment regimen with rituximab²³.

Most of these reports have come from the fields of oncology and transplantation. There has been little evidence regarding reactivation of resolved HBV in the autoimmune diseases²⁴, including a few case reports of reactivation of resolved HBV during treatments with anti-tumor necrosis factor (TNF) or methotrexate (MTX)^{25,26,27} and one prospective study suggesting the risk of reactivation of resolved HBV during biologic treatments²⁸. We investigated the risk of HBV reactivation during diverse immunosup-

From the Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

M. Kato, MD, PhD; T. Atsumi, MD, PhD; T. Kurita, MD; T. Odani, MD; Y. Fujieda, MD; K. Otomo, MD; T. Horita, MD, PhD; S. Yasuda, MD, PhD; T. Koike, MD, PhD, Department of Medicine II, Hokkaido University Graduate School of Medicine.

Address correspondence to Dr. M. Kato, Department of Medicine II, Hokkaido University Graduate School of Medicine, N15W7 Kita-Ku, Sapporo 060-8638, Japan. E-mail: ktmasar@med.hokudai.ac.jp

Accepted for publication June 10, 2011.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.

pressive therapies for autoimmune diseases in patients who were HBsAg-negative.

MATERIALS AND METHODS

Study design and patients. A total of 414 patients with active autoimmune diseases who would have immunosuppressive therapy were screened for HBsAg, anti-HBc, and anti-HBs (all by the enzyme immunoassay method) in our institution during the period July 2007 through March 2010. A total of 35 HBsAg-negative and anti-HBc-positive patients were identified (Table 1). These 35 patients were followed for 24 (range 8–124) weeks and their clinical outcomes were analyzed including serum levels of HBV-DNA (by polymerase chain reaction method), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) every 4 weeks during the immunosuppressive therapy for underlying autoimmune diseases. HBV-DNA was detected during the immunosuppressive therapy; HBsAg, anti-HBs, hepatitis B e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were also monitored every 4 weeks (all by the enzyme immunoassay method). AST/ALT elevation was considered significant if elevated more than 3 times the upper limit of normal.

Our study was performed in accord with the Declaration of Helsinki and the Principles of Good Clinical Practice. Approval was obtained from the local ethics committee.

Statistical analysis. Statistical analysis was performed by Student's t test, Mann-Whitney U test, chi-square test, or Fisher's exact test, as appropriate. P values < 0.05 were considered significant.

RESULTS

Risk analysis of HBV-DNA detection (HBV reactivation). Out of 414 patients screened in this study, 35 patients (8%) had negative HBsAg and positive anti-HBc. HBV-DNA was detected in 6 of these 35 patients during the immunosuppressive therapy. HBV-DNA turned positive between 4 and 8 weeks after the initiation of immunosuppressive therapy.

Table 1. Patients' characteristics (N = 35).

Characteristic	Value
Female, %	77 (27/35)
Age, yrs, median (range)	62 (30–80)
Diagnosis, n	
Systemic lupus erythematosus	12
Vasculitis syndrome	12
Rheumatoid arthritis	5
Polymyositis/dermatomyositis	2
Idiopathic thrombocytopenic purpura	2
Adult-onset Still's disease	1
Autoimmune hemolytic anemia	1
Prednisolone, mg/day, median (range)	60 (0–60)
Steroid pulse therapy, %	60 (21/35)
Immunosuppressant, %	60 (21/35)
Cyclophosphamide	13
Tacrolimus	4
Cyclophosphamide + tacrolimus	2
Methotrexate	1
Cyclosporin A	1
Biologics, %	17 (6/35)
Rituximab	3
Infliximab	1
Etanercept	1
Tocilizumab	1

There were no differences in sex, age, dose of prednisolone, and level of total serum immunoglobulin G between the patients in whom HBV-DNA was detected and the others (Table 2). Type of therapy, such as steroid pulse therapy, immunosuppressants, or biologics, did not correlate with the HBV reactivation. Baseline anti-HBs titer was significantly lower in the patients in whom HBV-DNA was detected compared with the other patients [2.83 (range 0.24–168.50) mIU/ml vs 99.94 (range 0.00–5342.98) mIU/ml, respectively; $p = 0.036$ by Mann-Whitney U test; Table 2].

Outcomes of patients with HBV reactivation. Outcomes of the 6 patients with HBV reactivation were as follows: HBV-DNA turned negative in 2 patients without NAA and one with NAA; 2 died due to bacterial sepsis; and 1 died due to autoimmune hemolytic anemia (Table 3). Significant elevation of AST and/or ALT was found in only 1 patient, but HBsAg converted to positive in 2 patients and HBeAg converted to positive in 1 patient (Table 3). The mortality rate was slightly higher in patients with HBV reactivation than in those without: 50% (3/6) versus 17% (5/29), respectively ($p = 0.10$, Fisher's exact test). Three representative clinical courses of patients with HBV reactivation are shown in Figure 1; a 77-year-old woman recovered with NAA (Figure 1A), a 78-year-old woman spontaneously recovered without NAA (Figure 1B), and a 58-year-old woman developed reverse seroconversions of both HBs and HBe (Figure 1C).

Anti-HBs titer. The titer of anti-HBs was monitored in each patient with HBV reactivation at baseline, at the time HBV-DNA was detected, and at the end of followup, but no particular fluctuation pattern was noted (Figure 2A). In patients without HBV reactivation, anti-HBs was measured at baseline and 8 weeks after the initiation of immunosuppressive therapy, showing persistent titers of anti-HBs: 99.4 (range 0.00–5342.98) mIU/ml versus 77.4 (range 0.00–2652.80) mIU/ml ($p = 0.66$, Mann-Whitney U test; Figure 2B).

Table 2. Comparison of patients in whom HBV-DNA was detected (HBV reactivation) or not detected.

Characteristic	HBV-DNA Detected, n = 6	HBV-DNA Not Detected, n = 29	p
Female, %	100 (6/6)	72 (21/29)	0.18
Age, yrs, median (range)	65 (30–78)	62 (34–80)	0.66
Prednisolone, mg/day, median (range)	60 (10–60)	60 (0–60)	0.80
Steroid pulse therapy, %	67 (4/6)	59 (17/29)	0.54
Immunosuppressant, %	83 (5/6)	55 (16/29)	0.21
Biologics, %	17 (1/6)	17 (5/29)	0.73
Total IgG at baseline, mg/dl, median (range)	1066 (787–4078)	1448 (192–2855)	0.36
Anti-HBs at baseline, mIU/ml, median (range)	2.83 (0.24–168.50)	99.94 (0.00–5342.98)	0.036*

* Mann-Whitney U test.

Table 3. Outcomes of patients with HBV reactivation.

Patient	Age/Sex	Diagnosis	Anti-HBs	Immunosuppressive Regimen				Time to		Outcome		
			at Baseline, mIU/l	PSL, mg	Steroid Pulse	Immuno-suppressant	Biologics	Weeks	AST/ALT Elevation	HBsAg	HBeAg	
1	77 F	RA + IP	168.5	60	+	TAC	-	4	-	-	-	Recovered with NAA
2	78 F	MPA	5.31	40	-	IVCY	-	8	-	-	-	Recovered without NAA
3	58 F	SLE	0.24	60	+	IVCY + TAC	-	4	-	+	+	Died due to sepsis
4	71 F	RA + EBV-LPD	0.28	10	-	-	RTX	4	-	-	-	Recovered without NAA
5	30 F	SLE	0.35	60	+	IVCY	-	8	+	-	-	Died due to sepsis
6	59 F	SLE	47.86	60	+	IVCY	-	4	-	+	-	Died due to hemolytic anemia

RA: rheumatoid arthritis; IP: interstitial pneumonia; MPA: microscopic polyangiitis; SLE: systemic lupus erythematosus; EBV-LPD: Epstein-Barr virus-related lymphoproliferative disease; PSL: prednisolone; TAC: tacrolimus; IVCY: intravenous cyclophosphamide; RTX: rituximab; NAA: nucleic acid analog; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

DISCUSSION

We demonstrate the potential risk of HBV reactivation during standard immunosuppressive therapy for autoimmune diseases in patients who are HBsAg-negative. There have been 3 case reports of reactivation of resolved HBV during treatments with anti-TNF or MTX: a patient with Crohn's disease receiving infliximab²⁵, a patient with ankylosing spondylitis receiving etanercept²⁶, and a patient with rheumatoid arthritis receiving low doses of MTX²⁷. In prospective studies, there have been conflicting results regarding the risk of reactivation of resolved HBV by biological agents; Charpin, *et al* reported the safety of anti-TNF agents in 21 patients with rheumatic diseases²⁹, and Vassilopoulos, *et al* reported the safety of anti-TNF agents in 19 patients with rheumatic diseases³⁰. In contrast with these small prospective studies, Urata, *et al* reported that reactivation of resolved HBV occurred in 7 of 135 patients with rheumatoid arthritis and that use of biologic agents represented a risk for reactivation²⁸. Therefore, the safety of immunosuppressive therapy in patients with resolved HBV with autoimmune diseases has not been established.

From our data, anti-HBs, the neutralizing antibody against HBV, may correlate with HBV reactivation. Anti-HBs titer was significantly lower in the patients with HBV reactivation than the others at baseline and tended to rise upon detection of HBV-DNA in some cases (Figure 1). Onozawa, *et al*³¹ reported a correlation between progressive decrease of anti-HBs and reactivation of resolved HBV after allogeneic hematopoietic stem cell transplantation. In our study, a progressive decrease of anti-HBs was not seen. Compared with reports of treatments in the field of oncology or transplantation, the current therapy for autoimmune diseases is less aggressive in terms of immunosuppression, thus anti-HBs titers are persistent in patients with autoimmune diseases. In contrast, the low titer of anti-HBs at baseline may represent the risk of HBV reactivation and could be one of the markers for the management of those patients.

All the subjects investigated in our study had active heterogeneous autoimmune diseases requiring aggressive immunosuppressive therapy, thus it was difficult to analyze a correlation between underlying disease activity and HBV reactivation. However, patients receiving cyclophosphamide had relatively higher risk of having HBV reactivation than the other patients [31% (4/13) vs 9% (2/22); $p = 0.12$, Fisher's exact test]. It could reflect that patients who received cyclophosphamide because of high disease activity had more risk of HBV reactivation.

The limitations of our study are the small sample size, large confidence intervals, and relatively short followup. In the published reports, reactivation of resolved HBV occurred 1 to 14 months after the initiation of immunosuppressive therapy^{25,26,28}, thus longer observation in large population studies may confirm our findings.

Our study suggests that reactivation of resolved HBV can occur during standard immunosuppressive therapy for autoimmune diseases, and that the low titer of baseline anti-HBs may carry its risk. Further study will be needed to establish the procedure for better management of HBV reactivation in the field of autoimmune diseases.

REFERENCES

- Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. *Lancet* 1975;2:528-30.
- Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. *Ann Intern Med* 1982;96:447-9.
- Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. *Ann Intern Med* 1981;94:744-8.
- Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. *Gastroenterology* 1975;68:105-12.
- Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving




Figure 1. Representative clinical courses of patients with HBV reactivation. A. A 77-year-old woman treated with NAA. B. A 78-year-old woman who spontaneously recovered without NAA. C. A 58-year-old woman who developed reverse seroconversion of both HBs and HBe. PSL: prednisolone; LVD: lamivudine; ETV: entecavir; AST: aspartate aminotransferase; ALT: alanine aminotransferase.




Figure 2. Change of anti-HBs titer in patients with HBV reactivation (A) and in those without reactivation (B). *4 to 8 weeks; **20 to 124 weeks.

- cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991;100:182-8.
6. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. *Hepatology* 2006;43:209-20.
 7. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007;45:507-39.
 8. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009;50:227-42.
 9. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. *N Engl J Med* 2001;344:68-9.
 10. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* 2006;131:59-68.
 11. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. *Hepatology* 1993;18:1313-8.
 12. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. *Gastroenterology* 1992; 103:1649-56.
 13. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. *J Clin Invest* 1994;94:907.
 14. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. *Hepatology* 2003;37:1172-9.
 15. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. *J Hepatol* 2005;42:302-8.
 16. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. *Clin Infect Dis* 2005;41:1277-82.
 17. Kitano K, Kobayashi H, Hanamura M, Furuta K, Ueno M, Rokuhara A, et al. Fulminant hepatitis after allogeneic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promoter region. *Eur J Haematol* 2006;77:255-8.
 18. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. *Leuk Lymphoma* 2005;46:1085-9.
 19. Sarecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. *J Infect Chemother* 2005;11:189-91.
 20. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. *Intern Med* 2006;45:721-4.
 21. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. *Ann Hematol* 2004;83:58-60.
 22. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by

- an escape mutant following rituximab therapy. *Blood* 2003;102:1930.
23. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. *Clin Infect Dis* 2008;47:e52-6.
 24. Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. *Expert Opin Biol Ther* 2011;11:533-44.
 25. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. *Inflamm Bowel Dis* 2007;13:508-9.
 26. Montiel PM, Solis JA, Chirinos JA, Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. *Liver Int* 2008;28:718-20.
 27. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. *J Gastroenterol* 2011;46:556-64.
 28. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. *Mod Rheumatol* 2011;21:16-23.
 29. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. *Arthritis Res Ther* 2009;11:R179.
 30. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. *Ann Rheum Dis* 2010;69:1352-5.
 31. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. *Transplantation* 2005;79:616-9.